TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Department of Defense (DOD) Healthcare beneficiary~* Parasitologic diagnosis of cutaneous Leishmania infection~(Inclusion criteria for randomization includes that must be Leishmania major species)~* Willing to locate to WRAMC area during treatment and perform subsequent follow-up visits if needed~(If not active duty on orders, then the participant will bear the cost of food and lodging during the initial 10-day outpatient treatment period at Walter Reed Army Medical Center)~* Able to provide informed consent~* All participants (both male and female) must agree to take precautions not to become pregnant or father a child for at least 2 months after receiving sodium stibogluconate~Exclusion Criteria:~* Unable to provide informed consent~* Pregnancy (females of child bearing potential must have negative urine human chorionic gonadotropic hormone \[HCG\] within 48 hours of the start of infusion period)~* History of hypersensitivity to pentavalent antimonials~* Serious medical illness:~  1. QTc interval \>/= 0.5 sec~ 2. severe cardiac disease~ 3. history of current pancreatitis~ 4. liver failure or active hepatitis with transaminases \>3X normal~ 5. renal failure or creatinine \>2.5~ 6. thrombocytopenia (platelets \<75,000)~ 7. white blood cell count \<2000~ 8. hematocrit \<25~ 9. absence of palpable extremity pulses in the limb requiring treatment~* History of serious allergic reaction to local anesthetics~* Location of lesion not amenable to local therapy (such as close to eye, mucous membranes, face, cartilage)~* Presence of pacemaker and/or other implanted metallic devices~* Breast feeding~* Men unwilling to avoid fathering a child during and/or in the two months following receiving the treatment~* Women unwilling to avoid pregnancy for at least two months after receiving the treatment~* More than 20 lesions, or multiple lesions which in the opinion of the investigator would not be well treated with heat therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sodium stibogluconate intravenous (Type: ACTIVE_COMPARATOR): 20 mg/kg/day Sodium stibogluconate intravenous
- ThermoMed device (Type: EXPERIMENTAL): ThermoMed device, single heat treatment at 50 degrees Celsius

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vacuum-formed Retainer Versus Bonded Retainer to Prevent Relapse After Orthodontic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with fixed appliances in both the maxilla and the mandible~Exclusion Criteria:~* Rapid Maxillary Expansion (RME) for patients with severe transversal malocclusion~* Treatment with segmented appliances~* Patients with craniofacial anomalies and patients requiring orthognatic surgery~* Patients with missing mandibular incisor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A: CTC retainer + Essix retainer (Type: EXPERIMENTAL): The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits.
- Group B: Essix retainer + Essix retainer (Type: ACTIVE_COMPARATOR): The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CellCept in p-ANCA Vasculitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
1. Active microscopic polyangiitis~2. Active urinary sediment (\>25 rbc/hpf, red cell casts or dysmorphic red cells)~3. Renal biopsy compatible with the diagnosis of microscopic polyangiitis, or diagnosis demonstrated by the presence of hematuria, proteinuria, and dysmorphic red blood cells, and / or red blood casts when biopsy is contraindicated.~4. Positive p-ANCA (MPO ELISA)~5. Serum creatinine \< 3.0mg/dl.~6. Age 18 years or over.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omentectomy and Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \> 35 Kg/m2~* Metabolic syndrome diagnosed~Exclusion Criteria:~* Type 1 diabetes~* Uncontrolled type 2 diabetes~* Cirrhosis or active hepatitis~* Pregnancy~* Recent MI or stroke

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Roux-en-Y Gastric Bypass/Omentectomy (Type: EXPERIMENTAL): Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
- Roux-en-Y Gastric Bypass alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be aged 18 years or above at baseline~* Diagnosed with any hepatobiliary condition requiring an elective major surgical resection under general anaesthetic.~* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol~Exclusion Criteria:~* Allergy/sensitivity to naloxone~* Female subjects who are pregnant or breast-feeding.~* Subjects who have received any other investigational agent within 2 months~* Subjects taking anticonvulsant medications for epilepsy~* Subjects who have a cardiac arrhythmia with an uncontrolled rate~* Subjects who have a history of chronic opioid use / chronic pain~* Any contraindication to intrathecal injection eg coagulopathy~* Documented history of obstructive sleep apnoea~* Treating clinician feels not in the patients best interests to be randomised

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naloxone (Type: EXPERIMENTAL): The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution.
- Saline (Type: PLACEBO_COMPARATOR): The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Milnacipran for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria~Exclusion Criteria:~* psychiatric illness,~* depression,~* suicidal risk,~* substance abuse,~* pulmonary dysfunction,~* renal impairment,~* active cardiac disease,~* liver disease,~* autoimmune disease,~* cancer,~* inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, twice daily for 12 weeks
- Milnacipran (Type: EXPERIMENTAL): Milnacipran 100mg/day (50mg BID \[twice a day\])

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women 18-85 years of age.~2. Scheduled for elective knee or hip arthroplasty with spinal anesthesia.~Exclusion Criteria:~1. Creatinine \>1.50 mg/dl.~2. History of clinically important current depression or currently on any prescribed anti-depressant medication.~3. Previously enrolled in any Xenoport trial.~4. Use of gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise) within one month.~5. Allergy to gabapentin or gabapentinoids (Lyrica, Horizant, Neurontin or Gralise).~6. Women who are pregnant or breastfeeding.~7. History of seizure disorder within the last one-year or taking medications for seizures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin enacarbil (Type: EXPERIMENTAL): Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged 18\~75 years old;~2. T2DM and treated with Metformin ≥ 1500mg/day constantly for at least 12 consecutive weeks;~3. 7.5% ≤ HbA1c ≤ 10.0% at screening;~4. 18.5 kg/m2 \< BMI \< 35.0 kg/m2 at screening;~Exclusion Criteria:~1. Any anti-diabetic therapy other than Metformin within 12 weeks before screening;~2. Received insulin therapy more than 30 days within 1 year before screening;~3. Fasting C-peptide \<0.81 ng/ml (0.27 nmol/L) at screening;~4. Medical history of severe hypoglycemia or frequent hypoglycemia, diabetic ketoacidosis, diabetes lactic acidosis or hyperosmotic nonketotic diabetic coma, severe cardio-cerebrovascular, unstable or rapidly progressive kidney disease, active liver diseases, diagnosed mental disease etc.~5. T1DM;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HMS5552 (Type: EXPERIMENTAL): 75mg BID
- Placebo (Type: PLACEBO_COMPARATOR): BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 and ≤75, male or female.~2. Asymptomatic Infection, Mild, or Common Type of COVID-19.~3. Initial positive test of SARS-Cov-2 within 5 days of randomization.~4. Initial onset of COVID-19 signs/symptoms within 3 days of randomization.~5. The Ct value of SARS-COV-2 nucleic acid test before randomization is ≤ 25, or the Ct value is \>25 and sarS-COV-2 serum IgG and IgM are negative.~Exclusion Criteria:~1. Transnasal high-flow oxygen therapy or non-invasive ventilation, invasive mechanical ventilation, or ECMO is required or anticipated to be urgently required.~2. Prior to current disease episode, any confirmed SARS-CoV-2 infection.~3. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis).~4. Receiving dialysis or have known moderate to severe renal impairment.~5. Known human immunodeficiency virus (HIV) infection.~6. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.s.~7. Oxygen saturation of ≤ 93% on room air obtained at rest within 24 hours prior to randomization..~8. Treatment with antivirals against SARS-CoV-2 within 14 days.~9. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance.~10. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days.~11. Has received or is expected to receive COVID-19 monoclonal antibody, convalescent COVID-19 plasma or other prohibited concomitant medication.~12. Females who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SSD8432 dose 1 (Type: EXPERIMENTAL): SSD8432 dose 1/ritonavir or placebo
- SSD8432 dose 2 (Type: EXPERIMENTAL): SSD8432 dose 2/ritonavir or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 45 years, inclusive.~* In good health with no history of major medical conditions~* A total body weight ≥ 50 kg and a body mass index (BMI) of \> 18kg/m2.~Exclusion Criteria:~* Acute or chronic medical illness~* Positive for Human Immunodeficiency Virus, Hepatitis B or C~* Nose or nasopharynx abnormalities~* Abnormal lung function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ALS-008176 (Type: EXPERIMENTAL): ALS-008176 drug substance for oral suspension
- vehicle alone (Type: PLACEBO_COMPARATOR): Vehicle alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Completion of study CLAF237A2307 within 4 weeks of entering into the extension~* Written informed consent~* Ability to comply with all study requirements~* Blood glucose criteria must be met~Exclusion Criteria:~* Premature discontinuation from study CLAF237A2307

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Living Well With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active RA symptoms~* Member of the BRASS registry at the Brigham and Women's Arthritis Clinic~* Ability to attend group and individual sessions consistently~Exclusion Criteria:~* RA has been in remission for one year~* Subjects who are currently enrolled in the Arthritis Foundation Self- Management course or any similar type of course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- IFS Intervention Group (Type: EXPERIMENTAL): None
- Education Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regorafenib Post-marketing Surveillance in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are treated with Regorafenib/ STIVARGA and meet the product label.~Exclusion Criteria:~* Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Vocational Rehabilitation on Mentally III Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Age, greater than or equal to 19 and less than 61.~* Enrollment in the TVAMC VRP~* Signed informed consent~* Chronic post-traumatic stress disorder~* Any race or ethnic origin~* Anticipation of remaining in the catchment area for the 12-month study duration~Exclusion Criteria:~* Lifetime history of severe traumatic brain injury that has resulted in severe cognitive impairment~* History of schizophrenia, schizoaffective, disorder, or bipolar I disorder~* Pending litigation~* In need of immediate detoxification.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Vocational Rehabilitation Program (VRP) (Type: ACTIVE_COMPARATOR): Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited
- Individual Placement and Support (IPS) (Type: EXPERIMENTAL): Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-response Effect of Dietary Nitrate on Muscle Function in Older Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~• In good health, as determined by the investigator's review of history (provided by subject at screening visit), physical examination, and routine blood and urine tests (done at screening visit)~Exclusion Criteria:~* Men and women \<65 or \>79 years of age~* Unable to provide informed consent~* Currently pregnant or lactating (given the age range for the study, verbal confirmation by subject is believed to be sufficient)~* Current smokers~* Significant orthopedic limitations or other contraindications to strenuous exercise~* Those taking phosphodiesterase inhibitors (e.g., Viagra)~* Those taking proton pump inhibitors, antacids, xanthine oxidase inhibitors, or on hormone replacement therapy~* Those taking anti-coagulants (e.g., Coumadin) or on anti-platelet therapy~* History of neuromuscular disease (e.g., cervical spondylotic radiculomyelpathy, lumbar spondylosis, amyotrophic lateral sclerosis, Guillain-Barré syndrome, and acquired demyelinating polyneuropathies), cardiovascular disease (e.g., \> stage I hypertension, heart failure, myocardial infarction/ischemia, significant myocardial or pericardial diseases (e.g. amyloidosis, constriction), moderate or severe valvular disease, renal disease, liver disease, or anemia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 3.3 mL/kg concentrated beet root juice \*depleted of nitrate\* Other names: Beet It Sport Nitrate 400 placebo
- low nitrate (Type: ACTIVE_COMPARATOR): 1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice \*depleted of nitrate\*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400
- high nitrate (Type: ACTIVE_COMPARATOR): 3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete